Similar results could be obtained when another BRAF inhibitor, dabrafenib, was used in patients with metastatic melanoma and further BRAF inhibitors (e.g., encorafenib) are now in clinical trials [25,26]. This evidence concerns the gene BRAF and metastatic melanoma.